Two more biotechs price IPOs, bringing total raise to record heights
Atea Pharmaceuticals and SQZ Biotechnologies have priced their public debuts, adding to this year’s record biotech IPO raise — a pot spilling over $13 billion that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
